Abstract
A large number of clinical trials have beenperformed using sulindac, a non-steroidal antiinflammatorydrug （NSAID）. Sulindac reduces thesize and number of large bowel polyps. However, itcannot be used for this indication in clinical settings as yet, because of the frequent occurrence of seriousgastrointestinal side effects. There are a number ofcases in which aggressive tumors developed despite areduction in the size of polyps. In addition toNSAIDs, clinical trials have been performed usingvitamins and dietary components. These show minimalside effects, but their efficacy is still insufficient forclinical use, and further studies are anticipated.
